Page 25 - AN-1-3
P. 25

Advanced Neurology                                           Early inhibition of PDK1 prevents AD-like pathology




                          A                                  B







                          C
                                                             D









                          E                                  F













                          G                                  H









            Figure 6. Reduced amyloid precursor protein (APP) expression in Pdk1 cKO/5×FAD mice. (A) Western blotting for full-length APP (APP-FL). Cortical
            samples from 5×FAD and Pdk1 cKO/5×FAD mice were used. β-actin was used as the loading control. (B) Quantification results of APP-FL. There was a
            significant difference in the APP levels between 5×FAD and Pdk1 cKO/5×FAD mice (n = 3 mice per group; ***P < 0.001). (C) Fluorescence IHC for APP.
            Brain sections at 4 months were used. The immunoreactivity of APP was qualitatively reduced in Pdk1 cKO/5×FAD mice compared with 5×FAD mice.
            The scale bar is 50 μm. (D) Western blotting for sAPPα and APP-CTF. Cortical samples from 5×FAD and Pdk1 cKO/5×FAD mice at 4 months were used.
            β-actin served as the loading control. (E) Quantification results of sAPPα and APP-CTF. There were significant differences in the levels of sAPPα and APP-
            CTF between 5×FAD and Pdk1 cKO/5×FAD mice (**P < 0.01; n = 3 mice per group). (F) Quantification results showing the ratio of sAPPα to APP. There
            was no significant difference between 5×FAD and Pdk1 cKO/5×FAD mice (n.s., not significant; n = 3 mice per group). (G) Western blotting for ADAM10
            and BACE1. β-actin was used as the loading control. (H) Quantification results of ADAM10 and BACE1. There were no significant differences in the levels
            of ADAM10 and BACE1 between 5×FAD and Pdk1 cKO/5×FAD mice (n.s., not significant; n = 3 mice per group).

            and BACE1. Since the levels of APP were significantly   deletion may not enhance the activity of  α-secretase or
            reduced in the Pdk1 cKO/5×FAD cortex, we reason that   β-secretase. In contrast, evidence has shown that BX912
            this may be responsible for the prevention of plaque   may promote α-secretase-dependent cleavage of APP .
                                                                                                           [22]
            deposition. In agreement with this, Duan  et al. have   We reason that the above discrepancy reflects the fact
            reported that CRISPR-Cas9-mediated KO of mutant    that  pharmacological  and  genetic  approaches  exhibit
            human APP gene reduces amyloid plaques and improves   different target selectivity and cell specificity . For
                                                                                                       [37]
            spatial working memory in 5×FAD mice.              instance, BX912 is known to inhibit a spectrum of kinases,
              On the other hand, no changes have been observed   including PDK1 [59,60] . In contrast,  Emx1-Cre-mediated
            in the  levels of ADAM10,  BACE1, and sAPPα in  Pdk1   gene recombination permits conditional inactivation of
            cKO/5×FAD cortices, suggesting a possibility that PDK1   PDK1 in neurons in the postnatal forebrain.


            Volume 1 Issue 3 (2022)                         9                       https://doi.org/10.36922/an.v1i3.153
   20   21   22   23   24   25   26   27   28   29   30